Sign In
Buy GBT
$68.49
+0 (+0%)
At Close: Jan 27, 2023
Novo Nordisk (NVO) to Tap Into SCD Space With Forma Acquisition
02:09pm, Friday, 02'nd Sep 2022 Zacks Investment Research
Novo Nordisk (NVO) inks agreement to acquire Forma Therapeutics for $1.1 billion. The company is looking to venture into the sickle cell disease and rare blood disorders space.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Global Blood
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 juillet 2022
07:59am, Monday, 29'th Aug 2022 GlobeNewswire Inc.
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 juillet 2022
3 Biopharmas on Buyout Watch
12:00pm, Monday, 22'nd Aug 2022 The Motley Fool
These three biotech companies could be headed for a buyout soon.
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates AAWW, GBT, CYBE, AVLR
09:42am, Monday, 22'nd Aug 2022
NEW YORK , Aug. 22, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches
Has Moderna Made a Bear Market Blunder?
01:15pm, Wednesday, 17'th Aug 2022 The Motley Fool
The company has stood pat while other businesses have been busy with M&A.
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GBT, AVLR, CYBE, SBCF
09:00am, Monday, 15'th Aug 2022
NEW YORK , Aug. 15, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches
Pharma Stock Roundup: PFE to Buy GBT, JNJ to Stall Baby Talc Sale Globally From 2023
01:50pm, Friday, 12'th Aug 2022 Zacks Investment Research
Pfizer (PFE) offers to buy Global Blood Therapeutics (GBT) for $5.4 billion in cash. J&J (JNJ) to discontinue selling talc-based baby powder globally from 2023.
Get ready for more merger mania in the pharma sector for the rest of the year
11:30am, Thursday, 11'th Aug 2022 MarketWatch
Pfizer’s $5.4 billion acquisition of Global Blood Therapeutics is the latest sign that cash-flush drug makers are ready to make some deals.
Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US
07:26pm, Tuesday, 09'th Aug 2022 Benzinga
Barclays says that CRISPR Therapeutics AG's (NASDAQ: CRSP) Q2 FY22 earnings release was largely incremental, highlighting the progress of multiple clinical programs, including the goal of on-tra
8 Analysts Have This to Say About Global Blood Therapeutics
03:13pm, Tuesday, 09'th Aug 2022 Benzinga
Within the last quarter, Global Blood Therapeutics (NASDAQ:GBT) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
0
7
Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings
03:02pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Global Blood (GBT) is set to be acquired by Pfizer for around $5.4 billion. The company missed estimates for earnings while beating the same for revenues in the second quarter of 2022.
Get ready for more merger mania in pharma sector the rest of the year
02:43pm, Tuesday, 09'th Aug 2022
Pfizer Inc.'s PFE, +0.24% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, +0.02% is the latest sign that cash-flush drug makers are ready to jump back into dealmaking.
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022
02:13pm, Tuesday, 09'th Aug 2022 Benzinga
Upgrades
For Nutrien Ltd (NYSE:NTR), Scotiabank upgraded the previous rating of Sector Perform to Sector Outperform. Nutrien earned $5.85 in the second quarter, compared to $2.08 in the year-ago quar
Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings
12:47pm, Tuesday, 09'th Aug 2022
Global Blood (GBT) is set to be acquired by Pfizer for around $5.4 billion. The company missed estimates for earnings while beating the same for revenues in the second quarter of 2022.
